Kornimate/medical-research-clean huggingface dataset:
the effect of showing photographs, videos and live images of their babies to mothers during milking

Conditions: Breast Milk Expression; Breast Milk Collection; Mother-Infant Interaction

Summary: the study was planned to determine the effect of showing photographs, videos and live images of premature babies who could not be breastfed in the neonatal intensive care unit to their mothers on the amount of breast milk, mother-infant attachment and breastfeeding self-efficacy. it is a randomized controlled experimental study.

separation of the baby from the mother, being admitted to the neonatal intensive care unit can quickly increase the mother's fears about her baby's health and appearance, it can be interpreted as a crisis for the family. when the baby is in the intensive care unit, it also becomes difficult for parents to participate in the care of the baby. in this case, one of the negative emotions that parents often experience is anxiety. in general, mothers experience more intense stress than fathers.the mother, who is away from her baby's care, feels tense, irritable and confused. she makes an effort to reach her baby, and when she fails to do so, she finds herself helpless and powerless. the neonatal intensive care nurse and the women's health nurse play a major role in the initiation of breastfeeding and the continuation of breastfeeding in pre-term newborns. early milking of mothers after premature birth increases breast milk production. despite early and frequent milking, some mothers may experience lower milk volume and milk production in the first few weeks. therefore, mothers with premature babies should practice frequent breastfeeding/milking, massage and compression, hot application, acupuncture, yoga and relaxation exercises, etc., in order to increase prolactin secretion and increase breast milk production. focused on non-pharmacological methods such as. another method that is considered effective is to show the mother a photo or video of the baby during milking. however, in the literature review, the number of available studies on this subject is only 2. one of these studies was done in 2020. the other study was done in 2021. more work is needed on this subject. the aim of this study was to determine the effects of watching photos, videos and live images of babies during milking on the amount of breast milk, mother-infant attachment and breastfeeding self-efficacy.

Eligibility criteria:
inclusion criteria: * staying of the baby in the neonatal intensive care unit * 34 weeks of gestation and below * mother's acceptance of the application * the mother's inability to breastfeed her baby * the mother has a smart mobile phone * mother's ability to read and write * being able to communicate with the mother (being able to read and write, speak turkish, etc.) exclusion criteria: * gestation week over 34 * the mother is breastfeeding her baby * being a smoker * having a systemic disease and constantly taking medication(s) * having a health problem that may affect the mother's milking (crack, mastitis, collapse etc.)

Keywords: prematüre neonatal intensive care breast milk
warrior care: naturalistic observation and harm reduction

Conditions: Post Traumatic Stress Disorder; Cannabis Use; Suicide

Summary: this study is looking at therapeutic potential of reducing tetrahydrocannabinol (thc) levels in regular cannabis smokers using contingency management (cm) intervention in a u.s. veteran population with post-traumatic stress disorder (ptsd).

in this trial, the investigators will recruit veterans with post-traumatic stress disorder (ptsd) who report using cannabis. veterans will be assigned (via participant self-selection) into either a naturalistic group that will be followed as the participants continue to use cannabis as they normally do (observation only), or into a "thc (tetrahydrocannabinol) reduction group" in which veterans are asked to switch from their typical cannabis product to using a lower thc/higher cannabidiol (cbd) product; adherence to this switch will be incentivized using a behavioral intervention called contingency management (cm).

Eligibility criteria:
inclusion criteria: * able to provide informed consent, iq score \>80, * served in branch of the us armed forces, report using cannabis, * report using cannabis (at least 4x/month) * test positive for thc in urine drug screen, * meet dsm-5 criteria for ptsd w/ sx of at least 6 months duration exclusion criteria: * urine drug screen positive for any other drugs * any clinically significant medical problems, * any current or past serious psychotic or bipolar disorder diagnosis as determined by scid-5 * at immediate high risk for suicide based on the c-ssrs * current sud other than nicotine use disorder, alcohol (mild or moderate) and cannabis use disorder * seeking treatment for cannabis use disorder
health economic assessment of tygacil® in the treatment of secondary peritonitis in intensive care units (icus)

Conditions: Peritonitis

Summary: the main goals of the study are: assessment of tygacil's cost-effectiveness; process cost analysis from a hospital perspective (including length of stay, treatment costs, side effect management costs, costs of monitoring, costs of diagnostic procedures, cost of care (tiss 10 score etc.); efficacy of tygacil under usual care conditions (cure rate).


Eligibility criteria:
inclusion criteria: * diagnosis of secondary peritonitis * treatment in an icu * patient age \>18 years
phase iii study of 0.1% tacrolimus(fk506) ophthalmic suspension in patients with vernal keratoconjunctivitis

Conditions: Keratoconjunctivitis; Conjunctivitis

Summary: to investigate the efficacy and safety of fk506 ophthalmic suspension on eye symptoms in patients with vernal keratoconjunctivitis

0.1% fk506 ophthalmic suspension were administered twice-a-day to patients with vernal keratoconjunctivitis in whom treatment with topical anti-allergic agents had been ineffective. the primary efficacy endpoint was the mean change from the baseline (before the treatment)in total score for objective clinical signs at the final observation. the safety of fk506 ophthalmic suspension was also investigated.

Eligibility criteria:
inclusion criteria: * vernal keratoconjunctivitis patients diagnosed by "guideline of diagnosis and treatment of allergic conjunctival disease" * patients with type i reactions defined by skin testing, antibody measurement, etc. * age over 6 years old exclusion criteria: * subjects receiving systemic administration or subconjunctival injection of corticosteroid or immunosuppressants(ophthalmic and systemic medications) within 2-weeks of initiation of the study * subjects needed to wear contact lenses during treatment period on a testing eye * subjects complicating an eye infection

Keywords: keratoconjunctivitis vernal keratoconjunctivitis fk506 tacrolimus
investigating safety, tolerability and efficacy of azd5363 in prostate cancer.

Conditions: Metastatic Castrate-Resistant Prostate Cancer (mCRPC),; Efficacy,; Safety and Tolerability,; Pharmacokinetics,; Pharmacodynamics,; Tumour Response.

Summary: to investigate the safety, tolerability and anti-tumour activity of azd5363, as monotherapy, in patients with metastatic castrate-resistant prostate cancer. azd5363 will be investigated in patients who have progressed after chemotherapy (part a) and in patients who have progressed before receiving chemotherapy (part b). recruitment into part a, group 1 has been suspended. a new design for this group is currently being evaluated. part a, group 2 patients (progressed after 1 or more 2nd generational anti-hormonal therapies) will receive azd5363 480mg bid intermittently (4 days on/3days off). part b will only start if there is evidence of anti-tumour activity along with azd5363 having an acceptable safety profile in part a. part b will be conducted in pre-chemotherapy patients on a dose and schedule selected from part a.

a phase ib multicentre study of azd5363 monotherapy to assess anti-tumour activity, safety, tolerability, and pharmacokinetics in patients with metastatic castrate-resistant prostate cancer (mcrpc) (pyrus)

Eligibility criteria:
inclusion criteria: * provision of informed consent * males aged 18 years and older * histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features for which no standard therapy is currently considered appropriate * documented evidence of metastatic castrate-resistant prostate cancer (mcrpc) * part a: patients must have received prior docetaxel-based chemotherapy for mcrpc and have a circulating tumour cell score of 5; * part b: patients must have progressed before receiving any chemotherapy for mcrpc; exclusion criteria: * any prior exposure to agents which inhibit akt as the primary pharmacological activity * any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis b, hepatitis c, and human immunodeficiency virus * spinal cord compression or brain metastases unless asymptomatic, treated, and stable and not requiring steroids * clinically significant abnormalities of glucose metabolism * major surgery within the previous 4 weeks

Keywords: metastatic castrate-resistant prostate cancer (mcrpc), adenocarcinoma of the prostate, prostate cancer, progressive disease, advanced disease.
study of two-step anesthesia in intravitreal injection

Conditions: Anesthesia, Local

Summary: a prospective, randomised, single-masked comparison of local anaesthetic approaches including topical anesthesia combined sub-conjunctival anesthesia (two-step anesthesia) for intravitreal injection #taivi# vs topical anesthesia

purpose: patient pain for intravitreal injection is evaluated between topical anesthesia combined sub-conjunctival anesthesia (two-step anesthesia) and topical anesthesia. methods: this prospective, randomized, single-blinded clinical trail is conducted at shanghai aier eye hospital. selected group of 60 patients will be randomized divided into 2 groups and underwent intravitreal injection of antiangiogenic agents and steroids. group1 uses two-step anesthesia , whereas group 2 uses topical anesthesia. a 5-point visual analogue pain scale is used to assess patients' pain score and surgeon's ease while operating. any complications therefore will be made note of.

Eligibility criteria:
inclusion criteria: neovascular age-related macular degeneration (wamd); pathologic myopia with choroidal neovascularisation (pm-cnv); diabetic macular edema (dme); retinal vein occlusion with macular edema (rvo-me); other diseases: uveitis with macular edema or choroidal neovascularisation. exclusion criteria: communication problems; allergy to amide-type local anaesthetic agents; history of vitreoretinal surgery or orbital surgery; orbital deformity; with episcleral adjunct surgery; trauma; keratitis; conjunctivitis.

Keywords: intravitreal injection pain anesthesia
zd1839 with hypofractionated radiation therapy with an immobilization device for advanced non-small cell lung cancer

Conditions: Non-Small Cell Lung Carcinoma (NSCLC)

Summary: the purpose of this study is to determine the safety and effectiveness of iressa when used with a short course of high dose radiation therapy in patients with lung cancer.

to estimate treatment-related esophageal, pulmonary, hematologic, and other toxicity of patients with non-small-cell lung cancer (nsclc) receiving zd1839 with hypofractionated thoracic radiotherapy (rt). all estimates of toxicity rates will be presented with corresponding confidence intervals using the exact method. the method of atkinson and brown will be used due to the two-stage sampling; the method of conover will be used for tumor response. to estimate tumor response rates of this treatment regimen and identify the most effective rt dose level, defined as the level associated with the best response rate. estimates of tumor response rates will be presented with corresponding confidence intervals using the exact method of conover. survival will be estimated by the kaplan-meier method.

Eligibility criteria:
inclusion criteria: * histologically confirmed non small cell lung cancer * stage iv needing radiation therapy to control symptoms * patients with brain metastases * unresectable or medically inoperable exclusion criteria: * small cell lung cancer * previous thoracic radiation therapy * oxygen-dependent patients * forced expiratory volume in 1 second (fev1) less than 1.5 * patients with active interstitial lung disease * patients with underlying lung disease

Keywords: advanced nsclc non-small cell lung carcinoma stage iv nsclc
randomized clinical trial (rct) to compare the efficacy of coban 2 versus ssb in the treatment of venous leg ulcers

Conditions: Venous Ulcer

Summary: the study purpose is to compare healing rates, cost effectiveness, quality of life and safety of 12 week compression therapy for the treatment of venous leg ulcers with the 3m™ coban™ 2 layer compression system versus short-stretch compression bandage.


Eligibility criteria:
inclusion criteria: * males or females, age 18 years or older * subjects having a venous leg ulcer (stage c6 according ceap classification, venous pathology proved by the presence of reflux (pr)), which is at least 1 cm in any dimension but not larger than 10 cm in any dimension and has at least 5 cm distance to additional ulcers. * subjects who are co-operative, willing to give written informed consent prior to study entry, and willing to comply with the study protocol. * subjects who are able to understand and answer questionnaire items. * subjects who can walk (with or without a walking aid). * subjects who have an abpi (ankle brachial pressure index) of treated leg greater or equal to 0,8 as measured within four weeks prior to enrollment. * subjects with venous incompetence as defined by reflux longer than 1,0 second in at least one of the following sites: groin \[femoral vein, junction of gsv\], mid thigh medial \[gsv\], hollow of the knee \[popliteal vein, junction of ssv\], mid calf \[ssv\] in the standing position, measured by doppler, preferably by duplex within the last 12 month without following active treatment of venous reflux. exclusion criteria: * subjects with an abpi \< 0.8 as measured within four weeks prior to enrollment. * subjects whose condition, in the opinion of the investigator, does not require or allow for compression therapy. * subjects where the potential study ulcer is infected, i.e. showing signs of clinical infection (not contamination) as evidenced by purulent, malodorous, or recent increase in drainage and/or peri-wound erythema or elevated temperature. * subjects receiving any systemic antibiotics. * subjects with diagnosed cancerous ulceration. * subjects with diabetic foot ulcers (do not exclude diabetics). * subjects with circumferential wounds. * subjects who started or significantly changed treatment with mood altering substances (e.g. antidepressant drugs) within two weeks prior to enrollment. * subjects who are participating in any prospective clinical study that can potentially interfere with this study. * subjects who are, in the opinion of the clinical investigator, unsuitable for enrollment in this study, for reasons not specified in the exclusion criteria. * subjects with known allergies against the following products: coban 2 layer compression system, rosidal k, rosidal soft, tegaderm foam, cavilon nsbf

Keywords: compression therapy venous leg ulcer sub bandage pressure
retrospective analysis of progression free survival and overall survival in a national cohort of patients with metastatic renal cell carcinoma treated in denmark from 2006-2010. darenca study 2.

Conditions: Renal Cell Carcinoma

Summary: non-interventional study. data obtained by patient chart reviews. retrospective analysis of progression free survival, time to treatment failure and overall survival in a national cohort of patients with metastatic renal cell carcinoma treated in denmark from 2006-2010 safety, prognostic factors, predictive factors and co-morbidity assessed by charlson comorbidity index. the following drugs will be evaluated: sunitinib, sorafenib, temsirolimus, everolimus, aldesleukin, interferon-alfa-2b.

no sampling. all eligible patients will be included.

Eligibility criteria:
inclusion criteria: metastatic renal cell carcinoma exclusion criteria: none

Keywords: metastatic renal cell carcinoma
evaluation of food additive contributions to obesity - feasibility study 1

Conditions: Obesity

Summary: the effects of food additives on body weight in humans are largely unknown. this is a before-and-after feasibility study in 5 obese adults who will be followed for 5 months. eligible participants will meet with the study team and will be taught how to limit the exposure to the studied food additives in their diet. participants will also be asked to limit eating out to a maximum of 2 days per week. primary outcomes in this study are recruitment rate, retention rate and adherence to the proposed dietary intervention.


Eligibility criteria:
inclusion criteria: * bmi\>/=30 kg/m2 * willingness and ability to follow the proposed dietary intervention * informed consent exclusion criteria: * previous or planned bariatric surgery in the next 1 year * current or planned participation in any structured weight-loss programs in the next 6 months * current or recent (within the last 6 months) use of weight-loss-inducing drugs or systemic steroids * bipolar disorder or attention deficit hyperactivity disorder * current use of anti-depressant or anti-psychotic medications * eating disorder or any other active disorder that may lead to significant weight changes * working night shifts * pregnancy or planned pregnancy in the next 1 year * uncontrolled diabetes mellitus or diabetes requiring treatment with \>2 oral diabetes medications or with insulin

Keywords: dietary modification
a phase 3, randomized, double-blind study for patients with invasive candidiasis treated with iv echinocandin followed by either oral ibrexafungerp or oral fluconazole

Conditions: Candidiasis, Invasive; Candidemia

Summary: this is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis included candidemia. subjects will receive intravenous echinocandin followed by oral ibrexafungerp (scy-078) vs intravenous echinocandin followed by oral fluconazole.


Eligibility criteria:
key inclusion criteria: * subject is a male or female adult ≥ 18 years of age on the day the study informed consent is signed. * subject has a diagnosis of candidemia and/or invasive candidiasis, defined as evidence of candida spp in either a bloodstream or tissue culture from a normally sterile site (excluding eye, cardiac tissue, bone tissue, central nervous system or prosthetic device) collected ≤ 4 days (within 96 hours) prior to initiation of iv echinocandin accompanied by any related clinical signs and/or symptoms (e.g., fever \[on one occasion \> 38°c\], hypotension, or local signs of inflammation). key exclusion criteria: * subject has any of the following forms of invasive candidiasis at screening: * septic arthritis in a prosthetic joint (septic arthritis in a native joint is allowed), * osteomyelitis, * endocarditis or myocarditis, * meningitis, endophthalmitis, or any central nervous system infection, * chronic disseminated candidiasis, * urinary tract candidiasis due to ascending candida infection secondary to unresolved obstruction or non-removeable device in the urinary tract, * patients with a sole diagnosis of mucocutaneous candidiasis, i.e., oropharyngeal, esophageal, or genital candidiasis; or candida lower urinary tract infection or candida isolated solely from respiratory tract specimens, * patients with concurrent invasive fungal infection other than candida spp., e.g., cryptococcosis, mold infection or endemic fungal infection, * patients who failed a previous antifungal therapy for the same infection, * subject has an inappropriately controlled fungal disease source (e.g., indwelling vascular catheter or device that cannot be removed or an abscess that cannot be drained) that is likely to be the source of the candidemia or invasive candidiasis. * subject has abnormal liver test parameters: alanine aminotransferase (alt) or aspartate aminotransferase (ast) levels \> 10-fold the upper limit of normal (uln). * subject has severe hepatic impairment and a history of chronic cirrhosis (child-pugh score \> 9). * subject has received more than 48 hours of non-echinocandin antifungal therapy for the treatment of invasive candidiasis (including candidemia) within 96 hours preceding initiation of iv echinocandin. o exception: receipt of antifungal therapy to which any candida spp. isolated in qualifying culture is not susceptible. * baseline qtcf ≥ 500 msec.
cardiometabolic risk factors and processed food

Conditions: Cardiac Disease; Cardiovascular Diseases; Nutrition; Nutritional Disease; Cardiometabolic Diseases; Cardiometabolic Risk Factors

Summary: cardiovascular diseases (cvd) remain a primary cause of chronic disability and mortality globally, with cardiometabolic risk factors such as hypertension, dyslipidemia, obesity, and diabetes significantly contributing to their development. poor nutrition is recognized as a modifiable key risk factor for cvd, representing a crucial area for prevention strategies. while current research often emphasizes overall dietary patterns and quality in cvd prevention, the spectrum of food processing, ranging from minimally processed to ultra-processed foods (upfs), can profoundly influence diet quality. ultra-processed foods, characterized by industrial processing techniques, additives, and special industrial ingredients, have been shown to potentially compromise the health benefits of food by reducing essential nutrients and bioactive compounds, introducing unhealthy elements, and altering food structures. emerging epidemiological evidence links higher upf consumption to an increased risk of obesity, hypertension, metabolic syndrome, and type 2 diabetes, with studies like the framingham offspring study indicating a positive association with cvd incidence. globally, upf consumption is on the rise, constituting a significant portion of daily energy intake. in turkey, data from the 2021 national nutrition and health survey reveals that a substantial 58% of adults consume processed foods daily . this is particularly concerning given turkey's high burden of cvd, which has been the leading cause of mortality for decades and is projected to increase further due to an aging population and rising rates of diabetes and obesity. notably, turkey has the highest rate of early myocardial infarction in europe. given the increasing consumption of upfs and their potential health implications, especially in a country with a high prevalence of cvd like turkey, understanding the relationship between dietary factors and cardiovascular health is critical. therefore, this study aims to investigate the association between processed food intake and cardiometabolic risk factors among adult individuals in türkiye.


Eligibility criteria:
inclusion criteria: * aged 18-65 years * volunteers patients exclusion criteria: * people under 18 years of ages * people over 65 years of ages * pregnant and breastfeeding women * individuals with active cancer or chronic illnesses

Keywords: processed food cardiometabolic risk obesity framingham risk score